Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study

Background Patients with advanced melanoma have limited treatment options after progression on immune checkpoint inhibitors (ICI). Lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, demonstrated an investigator-assessed objective response rate (ORR) of 36% in 66 pati...

Full description

Bibliographic Details
Main Authors: Jessica C Hassel, James Larkin, Madan Jagasia, Harriet Kluger, Omid Hamid, Jeffrey Weber, Jason Chesney, Amod Sarnaik, John M Kirkwood, Eric Whitman, Martin Wermke, Evidio Domingo-Musibay, Theresa Medina, Sajeve Thomas, Wen Shi, Karl D Lewis, Nikhil I Khushalani, Parameswaran Hari, Marlana Orloff, Mike Cusnir, Giao Q Phan, Andrew J S Furness, Michael E Egger, Friedrich Graf Finckenstein, Giri Sulur
Format: Article
Language:English
Published: BMJ Publishing Group 2022-12-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/12/e005755.full

Internet

https://jitc.bmj.com/content/10/12/e005755.full

Similar Items